The ultimate objective of the research projects in this program project application is to improve the therapeutic results for patients with leukemia and lymphoma. To achieve this objective, results of laboratory studies will be used to provide the basis for development of new treatment approaches in the clinic. At the same time, tumor samples from patients at diagnosis and/or relapse and normal lymphocytes and other cells from patients enrolled on clinical trials are studied to assess the responses to new treatments. As a results, the clinical projects in particular require research resources which extend beyond direct patient care and clinical laboratory functions. Without clinical research support provided in this Core it would not be possible to coordinate the proper collection of multiple research specimens from hundreds of patients/year, as well as th timely follow up of patients enrolled on research studies. Equally important for the success of the project is the collaboration of individuals in this core with staff from the biostatistic Core, who provide a quality control system for specimen tracking, computerized data entry, quality control of data as well as assist in the design and analysis of clinical research protocols. The purpose of the Clinical Research Support Core is to provide the following services that will be utilized by all of the research projects. 1. To collect research specimens and coordinate patient follow-up at DFCI and affiliated hospitals. 2. Act as liaison with outside physician and hospitals to coordinate the collection of research specimens and follow-up data. 3. To ensure that study parameters are followed, confirm eligibility and patient registration. 4. Ensure that study parameters are followed, confirm eligibility and patient registration. 4. Ensure accuracy of submitted data from outside sources. 5. To provide data management for the collection of individual patient information.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA066996-03
Application #
6269700
Study Section
Project Start
1998-05-14
Project End
1999-03-31
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
3
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Hogan, Louise E; Körner, Christian; Hobbs, Kristen et al. (2018) NK-cell activation is associated with increased HIV transcriptional activity following allogeneic hematopoietic cell transplantation. Blood Adv 2:1412-1416
Kelly, Rachel S; Lasky-Su, Jessica; Yeung, Sai-Ching J et al. (2018) Integrative omics to detect bacteremia in patients with febrile neutropenia. PLoS One 13:e0197049
Nakamura, Makoto; Wu, Lizi; Griffin, James D et al. (2018) Notch1 activation enhances proliferation via activation of cdc2 and delays differentiation of myeloid progenitors. Leuk Res 72:34-44
Gechijian, Lara N; Buckley, Dennis L; Lawlor, Matthew A et al. (2018) Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. Nat Chem Biol 14:405-412
Chu, S Haihua; Song, Evelyn J; Chabon, Jonathan R et al. (2018) Inhibition of MEK and ATR is effective in a B-cell acute lymphoblastic leukemia model driven by Mll-Af4 and activated Ras. Blood Adv 2:2478-2490
Sridhar, Radhakrishnan; Takei, Hisashi; Syed, Riyaz et al. (2018) Styryl Quinazolinones as Potential Inducers of Myeloid Differentiation via Upregulation of C/EBP?. Molecules 23:
Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Wang, Jinhua; Erazo, Tatiana; Ferguson, Fleur M et al. (2018) Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazipinones as Inhibitors of Kinases and Bromodomains. ACS Chem Biol 13:2438-2448
Fathi, Amir T; Erba, Harry P; Lancet, Jeffrey E et al. (2018) A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML. Blood 132:1125-1133
Cortes, Jorge E; Douglas Smith, B; Wang, Eunice S et al. (2018) Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol 93:1301-1310

Showing the most recent 10 out of 376 publications